CVKD (Cadrenal Therapeutics) Short-Term Debt : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Short-Term Debt?

Cadrenal Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.

Cadrenal Therapeutics's annual Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2022 ($0.04 Mil) but then declined from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.00 Mil).

Cadrenal Therapeutics Short-Term Debt Historical Data

The historical data trend for Cadrenal Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Short-Term Debt Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Short-Term Debt

0.04

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Debt	Get a 7-Day Free Trial					-	-	-	-	-

Cadrenal Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cadrenal Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029